Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Recurrence

Rectal Neoplasms

Disease Attributes

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Vitamins

Oxaliplatin

Leucovorin

Fluorouracil

Capecitabine

Levoleucovorin

Antimetabolites

Folinic Acid

Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy

Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)

Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)

CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)

mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.

Capecitabine: 2000 mg/m2/day, twice daily, days 1-14

5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

Surgery plus Adjuvant chemotherapy

Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV

CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)

mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.

Capecitabine: 2000 mg/m2/day, twice daily, days 1-14

5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV

CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)

mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.

Capecitabine: 2000 mg/m2/day, twice daily, days 1-14

5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

Chemotherapy

Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy

Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)

Preoperative radiotherapy

Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.

Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection

Procedure

Yuichiro Tsukada, MD,PhD

Masaaki Ito, MD, PhD

Nobuhiro Takiguchi

Kazuhiro Yoshida

Shigeki Yamaguchi

Mitsugu Sekimoto

Mamoru Shimomura

Masazumi Okajima

Yoshitsugu Tajima

Hiroyuki Bando

Masaaki Ito

Hideyuki Ishida

Ryo Inada

Hideo Baba

Kazuyuki Kawamoto

Yoshito Akagi

Takaya Kobatake

Tadahiko Masaki

Koki Otsuka

Keisuke Uehara

Yasumasa Takii

Naohiro Tomita

Yoshihiro Akazai

Takeshi Kato

Kiyoshi Maeda

Yusuke Nishizawa

Hideki Yamagami

Kou Miura

Akio Shiomi

Tsunekazu Mizushima

Shu Okamura

Junji Okuda

Hideki Ueno

Yukihide Kanemitsu

Yoshihisa Saida

Kimihiko Funahashi

Yusuke Kinugasa

Akihiko Tsuchida

Keiichi Takahashi

Shin Fujita

Toshihiko Sato

Manabu Shiozawa

Tadao Fukushima

Jun Watanabe

Masafumi Inomata

Yuichi Takayama

Hitoshi Ojima

JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.

In all, 110 patients from 43 Japanese institutions will be recruited over a period of 6 years. Eligible patients would be registered and randomly assigned to each group with an allocation ratio of 1:1. The primary endpoint is local relapse-free survival. The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions), and quality of life after surgery.

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

JCOG1801: A Phase III Randomized Controlled Trial Comparing Surgery Plus Adjuvant Chemotherapy With Preoperative Chemoradiotherapy Followed by Surgery Plus Adjuvant Chemotherapy for Locally Recurrent Rectal Cancer (RC-SURVIVE Study)

the period from registration in the trial to either the first event of local relapse or death from any cause and censored at the last date of contact for a living patient

s the time from registration to death from any cause and censored at the last date of contact for a living patient

the time from registration to either the first incidence of relapse or death from any cause and censored at the last date of contact for a living patient

Proportion of patients with pathological R0 resection

Pathological complete response rate (arm B)

Proportion of patients who completed the protocol treatment

Incidence of adverse events (adverse reactions)

QOL after surgery based on the Trial Outcome Index-Physical/Functional/Colorectal (TOI-PFC) \[0(better)-84(worse)\]

Japan Clinical Oncology Group

Japan Agency for Medical Research and Development

National Cancer Center Hospital East

Participants of this group are as controls.

Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.

Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.

Yu Zhang, PhD

Limin Ma, PhD

The aim of this study is to investigate kinematics of knees of patients with tumor around knee after microwave ablation with plate internal fixation

The control group was recruited from healthy subjects. The experimental group was recruited from patients with tumor around knee after microwave ablation with plate internal fixation.

Kinematics of Knees of Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation

Kinematics of the Healthy Knee and the Surgery Knee in Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation.

The gait cycle include seven key events (e.g. initial contact), and each gait has six degrees of freedom, including knee flexion/extension, internal/external rotation, adduction/abduction, anterior/posterior translation, distal/proximal translation, medial/lateral translation. The unit of angle is degree and that of translation is millimetre.

Medical Center of Assessment, Prevention and Treatment of Bone & Joint Diseases, Guangdong, China

Guangzhou General Hospital of Guangzhou Military Command

chief surgeon, associate professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer	NCT04288999	Rectal Cancer R...	Chemotherapy Preoperative ra... Procedure	20 Years - 80 Years	National Cancer Center Hospital East
Kinematics of Knees of Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation	NCT03135613	Knee Tumor Microwave	Procedure	- 40 Years	Guangzhou General Hospital of Guangzhou Military Command
Kinematics of Knees of Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation	NCT03135613	Knee Tumor Microwave	Procedure	- 40 Years	Guangzhou General Hospital of Guangzhou Military Command

Spots Global Cancer Trial Database for procedure

Every month we try and update this database with for procedure cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for procedure

Every month we try and update this database with for procedure cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for procedure cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.